FPR2 and metabolic dysfunction-associated steatohepatitis: To confirm whether estrogen-mediated Fpr2 expression reduced susceptibility to NASH progression in female mice, both ovaries were removed from WT female mice, and chow or CDAHFD was given to these female mice for 12 weeks (Supplementary Fig. 14a).